MOG-induced EAE Efficacy Model for MS Research
Experimental autoimmune encephalomyelitis (EAE) is primarily used as a non-clinical model of autoimmune inflammatory diseases of the CNS, and resembles many aspects of human Multiple Sclerosis (MS). The myelin oligodendrocyte glycoprotein (MOG)-induced EAE model is ideal for exploring this immune-mediated mechanism of neuroinflammation and demyelination. Our MOG-induced EAE model is well-characterized and commonly used in the development of a variety of MS therapeutics. MDB also provides OECD GLP-certified clinical batch release testing services for Copaxone® generics (Glatiramer Acetate).
At MD Biosciences, the Multiple Sclerosis efficacy model contains immunization with Myelin Oligodendrocyte Glycoprotein (MOG35-55), which induces a chronic form of EAE in mice.
Inflammatory biomarkers provide information related to mechanisms contributing to inflammatory pain and how well compounds modulate the inflammatory and/or pain response.
Cytokines by multiplex analysis. Two markers from a cytokine profile in MOG-induced animals that were treated with vehicle or positive control. Day 15 was compared to day 26.
Review the complete dataset.